Study Phase 2

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma

Trial Information

Generic NameGolimumabProduct NameSIMPONI®Therapeutic AreaRespiratory Tract (Lung and Bronchial) DiseasesEnrollment309% Female56%% White88%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberC0524T03Data PartnerJohnson & JohnsonCondition StudiedAsthmaMean/Median Age (Years)50.1

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.